Vahidy F S, Rahbar M H, Lal A P, Grotta J C, Savitz S I
Department of Neurology, University of Texas Medical School, Houston, TX, USA.
Division of Epidemiology, Human Genetics and Environmental Sciences (EHGES), School of Public Health, The University of Texas Health Science Center, Houston, TX, USA.
Int J Stroke. 2015 Aug;10(6):882-6. doi: 10.1111/j.1747-4949.2012.00945.x. Epub 2012 Dec 11.
To determine factors associated with patients refusing IV t-PA for suspected acute ischemic stroke (AIS), and to compare the outcomes of patients who refused t-PA (RT) with those treated with t-PA.
Patients who were treated with and refused t-PA at our stroke center were identified retrospectively. Demographics, clinical presentation, and outcome measures were collected and compared. Clinical outcome was defined as excellent (mRS: 0-1), good (mRS: 0-2), and poor (mRS: 3-6).
Over 7·5 years, 30 (4·2%) patients refused t-PA. There were no demographic differences between the treated and RT groups. The rate of RT decreased over time (OR 0·63, 95% CI 0·50-0·79). Factors associated with refusal included a later symptom onset to emergency department presentation time (OR 1·02, 95% CI 1·01-1·03), lower NIHSS (OR 1·11, 95% CI 1·03-1·18), a higher proportion of stroke mimics (OR 17·61, 95% CI 6·20-50·02) and shorter hospital stay (OR 1·32, 95% CI 1·09-1·61). Among patients who were subsequently diagnosed with ischemic stroke, only length of stay was significantly shorter for refusal patients (OR 1·37, 95% CI 1·06-1·78). After controlling for mild strokes and stroke mimics, clinical outcome was not different between the groups (OR 1·61, 95% CI 0·69-3·73).
The incidence of patients refusing t-PA has decreased over time, yet it may be a cause for t-PA under-utilization. Patients with milder symptoms were more likely to refuse t-PA. Refusal patients presented later to the hospital and had shorter hospital stays. One out of six refusal patients (16·6%) had a stroke mimic.
确定与疑似急性缺血性卒中(AIS)患者拒绝静脉注射组织型纤溶酶原激活剂(IV t-PA)相关的因素,并比较拒绝使用t-PA的患者(RT)与接受t-PA治疗的患者的结局。
回顾性确定在我们卒中中心接受t-PA治疗和拒绝t-PA治疗的患者。收集并比较人口统计学、临床表现和结局指标。临床结局定义为良好(改良Rankin量表[mRS]:0-1)、较好(mRS:0-2)和较差(mRS:3-6)。
在7.5年期间,30例(4.2%)患者拒绝使用t-PA。治疗组和RT组之间在人口统计学上无差异。RT率随时间下降(比值比[OR]0.63,95%置信区间[CI]0.50-0.79)。与拒绝相关的因素包括从症状出现到急诊就诊时间较晚(OR 1.02,95%CI)、美国国立卫生研究院卒中量表(NIHSS)评分较低(OR 1.11,95%CI 1.03-1.18)、卒中模拟疾病比例较高(OR 17.61,95%CI 6.20-50.02)以及住院时间较短(OR 1.32,95%CI 1.09-1.61)。在随后被诊断为缺血性卒中的患者中,仅拒绝治疗的患者住院时间显著较短(OR 1.